Clinical Trial Update: An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201) [Phase 2]

View source ↗

Summary

Phase 2 trial update of ALLN-346 (engineered urate oxidase) in hyperuricemic subjects has completed enrollment and status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Diseases
• Gout
• Hyperuricemia

Drugs mentioned

• ALLN-346 (engineered urate oxidase)

Snippet

Sponsor: Allena Pharmaceuticals | Conditions: Hyperuricemia, Gout | Phase 2 | Status: COMPLETED